MedPath

Evaluation of the effect of cannabidiol in the treatment of dystonia

Phase 3
Recruiting
Conditions
dystonia.
Dystonia
Registration Number
IRCT20211019052811N1
Lead Sponsor
Mashhad University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Patients with focal-generalized dystonia
Failure to improve the patient's dystonic symptoms with previous drug treatments

Exclusion Criteria

Evidence that dystonia is secondary to other diseases
History of liver disease
Pregnancy or intent to conceive or breastfeed
History of dystonic surgery, including deep brain stimulation and destructive surgery

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Intensity of dystonia motion symptoms based on Van Marsden Scale and Global Dystonia Scale and TWSTRS. Timepoint: Before the intervention (0), then 3, 6, and 9 weeks after the start of the intervention or placebo. Method of measurement: Van Marsden Scale and Global Dystonia Scale and TWSTRS.
Secondary Outcome Measures
NameTimeMethod
Quality of life using SF-36 questionnaire. Timepoint: Before the intervention (0), then 3, 6, and 9 weeks after the start of the intervention or placebo. Method of measurement: SF-36 questionnaire.
© Copyright 2025. All Rights Reserved by MedPath